Viral Hepatitis :
Ribavirin is indicated in viral hepatitis such as Hepatitis C, Hepatitis B and Hepatitis A. I.
Hepatitis C:
Ribavirin is indicated for the treatment of chronic hepatitis C. It has been reported that when ribavirin is combined with interferon, the antiviral effect is enhanced. Both are given for 24 weeks. Serum ALT falls, loss of serum HCV RNA is sustained in 40% and necro inflammatory activity is reduced
on liver biopsy. FDA (USA) has approved the combination of ribavirin + interferon for the treatment of chronic hepatitis C.
Hepatitis B :
Chronic hepatitis B treated with a six months course of ribavirin had a modest decrease in HBV DNA that was associated with considerable reduction in disease activity as measured by ALT activity. It is also suggested that ribavirin may ameliorate disease activity and be useful as adjunctive therapy, possibly in combination with interferon for the treatment of chronic hepatitis B.
Influenza :
The treatment of influenza is usually symptomatic and supportive. Studies have shown limited efficacy in the treatment of both influenza A and B.
Measles :
Anecdotal reports of ribavirin in patients which suggest that it may be effective particularly in immunocompromised patients.
Haemorrhagic fever :
The treatment of haemorrhagic fever is primarily symptomatic. However. ribavinn has been reported to reduce mortality in patients with lassa fever, haemorrhagic fever with renal syndrome and possibly
Crimean-Congo haemorrhagic fever. Ribavirin has also been tried in the related hanta virus pulmonary syndrome, preliminary results did not indicate an improvement in mortality.
Dosage Forms:
Each tablet contains Ribavirin——400mg